Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease. The Company’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is the subject of three ongoing formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease, (ClinicalTrials.gov NCT02939547, NCT02912793 and NCT03893071). The company is planning an early phase clinical trial using Trappsol® Cyclo™ intravenously in Alzheimer’s Disease based on encouraging data from an Expanded Access program for late-onset Alzheimer’s Disease (NCT03624842). Additional indications for the active ingredient in Trappsol® Cyclo™ are in development.
Company profile
Ticker
CYTH
Exchange
Website
CEO
Nathan Scott Fine
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
CTD HOLDINGS INC, CYCLODEXTRIN TECHNOLOGIES DEVELOPMENT INC
SEC CIK
Corporate docs
IRS number
593029743
CYTH stock data
Press releases
Cyclo Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results
16 Aug 22
Cyclo Therapeutics to Present at the China NPC Association Meeting
8 Aug 22
Cyclo Therapeutics to Present at the NNPDF-INPDA Conferences 2022
21 Jul 22
Cyclo Therapeutics to Present at the World Orphan Drug Congress USA 2022
11 Jul 22
Cyclo Therapeutics to Present at the 2022 NPC Patient and Family Conference Hosted by the Australian NPC Disease Foundation
21 Jun 22
Investment data
Securities sold
Number of investors
Calendar
15 Aug 22
16 Aug 22
31 Dec 22
Financial summary
| Quarter (USD) | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 7.45M | 7.45M | 7.45M | 7.45M | 7.45M | 7.45M |
| Cash burn (monthly) | 1.45M | 334.17K | 1.15M | 1.09M | 1.45M | 1.24M |
| Cash used (since last report) | 2.28M | 524.99K | 1.81M | 1.71M | 2.28M | 1.94M |
| Cash remaining | 5.18M | 6.93M | 5.64M | 5.75M | 5.17M | 5.51M |
| Runway (months of cash) | 3.6 | 20.7 | 4.9 | 5.3 | 3.6 | 4.5 |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 2 Aug 22 | Ostronic Francis Patrick | Common Stock | Grant | Acquire A | No | No | 0 | 7,162 | 0 | 145,687 |
| 2 Aug 22 | Toig Randall M. | Common Stock | Grant | Acquire A | No | No | 0 | 3,093 | 0 | 51,625 |
| 2 Aug 22 | Sieger Markus | Common Stock | Grant | Acquire A | No | No | 0 | 5,762 | 0 | 91,674 |
| 20 May 22 | Ostronic Francis Patrick | Common Stock | Buy | Acquire P | No | No | 2.0399 | 4,988 | 10.18K | 138,525 |
| 20 May 22 | Ostronic Francis Patrick | Common Stock | Buy | Acquire P | No | No | 2 | 12 | 24 | 133,537 |
| 16 May 22 | Tate Jeffrey | Common Stock | Buy | Acquire P | No | No | 2.118 | 3,000 | 6.35K | 32,160 |
Institutional ownership, Q1 2022
7.6% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 14 |
| Opened positions | 12 |
| Closed positions | 4 |
| Increased positions | 1 |
| Reduced positions | 0 |
| 13F shares | Current |
|---|---|
| Total value | 4.17M |
| Total shares | 643.49K |
| Total puts | 0 |
| Total calls | 0 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Vanguard | 255.07K | $808K |
| Hirschman Orin | 209.38K | $2.79M |
| Renaissance Technologies | 75.79K | $240K |
| Geode Capital Management | 48.32K | $153K |
| STT State Street | 28.3K | $90K |
| BLK Blackrock | 18.2K | $58K |
| UBS UBS Group AG - Registered Shares | 2.29K | $7K |
| WFC Wells Fargo & Co. | 2.05K | $6K |
| Tower Research Capital | 1.51K | $5K |
| C Citigroup | 1.23K | $4K |
Financial report summary
?Competition
Orphazyme A/SContent analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. freshman Avg
|
|
New words:
bore
Removed:
investor, partially
Financial reports
Current reports
8-K
Submission of Matters to a Vote of Security Holders
24 Jun 22
8-K
Departure of Directors or Certain Officers
2 Mar 22
8-K
Cyclo Therapeutics Announces Pricing of $11.7 Million Underwritten Public Offering of Common stock
19 Nov 21
8-K
Termination of a Material Definitive Agreement
16 Nov 21
8-K
Departure of Directors or Certain Officers
1 Sep 21
8-K
Entry into a Material Definitive Agreement
16 Aug 21
8-K
Departure of Directors or Certain Officers
25 Jun 21
8-K
Other Events
22 Dec 20
8-K
Cyclo Therapeutics Announces Pricing of $12.5 Million Public Offering
11 Dec 20
8-K
Material Modifications to Rights of Security Holders
10 Nov 20
Registration and prospectus
424B5
Prospectus supplement for primary offering
18 Nov 21
424B5
Prospectus supplement for primary offering
16 Nov 21
424B5
Prospectus supplement for primary offering
16 Aug 21
S-3/A
Shelf registration (amended)
21 May 21
S-3
Shelf registration
19 Mar 21
424B4
Prospectus supplement with pricing info
11 Dec 20
424B4
Prospectus supplement with pricing info
10 Dec 20
S-1MEF
Registration of additional securities for an S-1
9 Dec 20
8-A12B
Registration of securities on exchange
8 Dec 20
S-1/A
IPO registration (amended)
3 Dec 20
Other
EFFECT
Notice of effectiveness
1 Jun 21
CORRESP
Correspondence with SEC
25 May 21
UPLOAD
Letter from SEC
23 Mar 21
EFFECT
Notice of effectiveness
9 Dec 20
CERT
Certification of approval for exchange listing
8 Dec 20
CORRESP
Correspondence with SEC
3 Dec 20
CORRESP
Correspondence with SEC
3 Dec 20
UPLOAD
Letter from SEC
5 Oct 20
EFFECT
Notice of effectiveness
15 Jul 19
CORRESP
Correspondence with SEC
9 Jul 19
Ownership
4
Cyclo Therapeutics / Randall M. Toig ownership change
4 Aug 22
4
Cyclo Therapeutics / Markus Sieger ownership change
4 Aug 22
4
Cyclo Therapeutics / Francis Patrick Ostronic ownership change
4 Aug 22
4
Cyclo Therapeutics / Francis Patrick Ostronic ownership change
23 May 22
4
Cyclo Therapeutics / JEFFREY TATE ownership change
16 May 22
4
Cyclo Therapeutics / Francis Patrick Ostronic ownership change
4 May 22
4
Cyclo Therapeutics / Francis Patrick Ostronic ownership change
4 May 22
4
Cyclo Therapeutics / Markus Sieger ownership change
4 May 22
4
Cyclo Therapeutics / Randall M. Toig ownership change
4 May 22
4
Cyclo Therapeutics / JEFFREY TATE ownership change
29 Apr 22
Reddit threads
Daily Discussion Thread - August 16th, 2022
16 Aug 22
Daily Discussion Thread - August 15th, 2022
15 Aug 22
Post a penny stock you think could 100x or more in 10 years. My pick $QNCCF/$QNC
24 Jul 22
Daily Discussion Thread - May 13th, 2022
13 May 22
Nine Years Ago, someone here asked what stock to hold for 20 years. Whats your pick for the next 9 years?
11 Apr 22
What are you bagholding and why?
15 Feb 22
Stock Watch List December 6, 2021
6 Dec 21
Morning Update for Monday, 12/6/21
6 Dec 21
Daily Discussion Thread - November 16th, 2021
16 Nov 21
Daily Discussion Thread - November 15th, 2021
15 Nov 21